title: [Analysis of the effects on menopausal symptoms, quality of Life, and cardiovascular risk factors of five different therapy in women at early stage of menopause].
abstract: OBJECTIVE
  To explore the effects of five different therapy in women at early stage of menopause on menopausal symptoms, quality of Life and cardiovascular risk factors.
  
  
  METHODS
  A total of 140 women at early stage of menopause were randomly divided into five groups. Thirty women took Conjugated estrogen and medroxyprogesterone acetate(CEE+ MPA) sequential therapy, 27 women took estradiol valerate and medroxyprogesterone acetate(E2V+ MPA) sequential therapy, 26 women took estradiol valerate and Progesterone Soft Capsules(E2V+ P) sequential therapy, 30 women took Kuntai capsule, and 27 took Cohosh extract.Patients in the Menopausal Hormone Therapy(MHT) groups took twelve cycles of treatment course, in the botanical drug and Chinese patent drug groups took twelve months. The KMI scalewas used to measure the level of menopausal symptoms. MENQOL scale was used to measure the health-related quality of life before and at the 3(rd) month, 6(th) month, 9(rd) month and 12(th) month after the treatment. Some serological indicators which related to cardiovascular risk factors were collected before and at the 12(th) month after the treatment.
  
  
  RESULTS
  (1) KMI: It showed that the KMI in five groups after the treatment were significantly different(P<0.01), the group of CEE+ MPA decreased most(13±1). The KMI after the treatment were all significantly lower than that before. (2)MENQOL: It showed that the MENQOL in five groups were significantly different(P<0.01), the group of CEE+ MPA decreased most (84±3), then the group of Kuntai(85±3). The MENQOL after the treatment were all significantly lower than that before. (3)The change of cardiovascular risk factors: it showed that the serological indicators FBGin group of CEE+ MPA after the treatment were significantly lower than that before(P<0.05); the TC, LDL, FI in group of E2V+ MPA after the treatment were significantly lower than that before(P<0.05); the FBG, FI in group of E2V+ P after the treatment were significantly lower than that before(P<0.05).
  
  
  CONCLUSIONS
  The MHT, botanical drug and Chinese patent drug have great clinical curative effects in treating perimenopause syndrome, improving the health-related quality of life and decreasing risk factors of cardiovascular disease.With rare adverse events and good clinical medication safety, they could be widely applied to clinic to women at early stage of menopause who was suffering menopausal symptoms.
authors.affiliation: Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing 100730, China.
authors.forename: W
authors.initials: W
authors.lastname: Xue
authors.forename: A J
authors.initials: AJ
authors.lastname: Sun
authors.forename: T P
authors.initials: TP
authors.lastname: Zheng
authors.forename: J F
authors.initials: JF
authors.lastname: Jiang
authors.forename: Y P
authors.initials: YP
authors.lastname: Wang
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
authors.forename: F L
authors.initials: FL
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Deng
authors.forename: Y F
authors.initials: YF
authors.lastname: Wang
mesh_terms: D002318:Cardiovascular Diseases; D004958:Estradiol / Q000031:analogs & derivatives; D004966:Estrogens, Conjugated (USP); D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D017258:Medroxyprogesterone Acetate; D008593:Menopause; D047648:Perimenopause; D011374:Progesterone; D011788:Quality of Life; D012307:Risk Factors
chemical_list: D004966:Estrogens, Conjugated (USP); D011374:Progesterone; D004958:Estradiol; D017258:Medroxyprogesterone Acetate